NEW YORK (GenomeWeb) – Pathway Genomics has signed an agreement to make its next-generation sequencing-based clinical genetic tests available in Mexico through health services provider Salud Interactiva, the companies announced today.

Specific terms of the deal were not disclosed.

Pathway sells a variety of NGS assays including ones for diet and weight loss, circulating tumor DNA mutations, hereditary cancer, and carrier screening, as well as metabolic response for commonly prescribed medications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sep
20

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.